Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPFGet Free Report) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 10,400 shares, a decrease of 9.6% from the December 31st total of 11,500 shares. Based on an average daily volume of 7,300 shares, the short-interest ratio is presently 1.4 days.

Antibe Therapeutics Price Performance

ATBPF opened at $0.75 on Wednesday. The business has a 50 day simple moving average of $0.66 and a two-hundred day simple moving average of $0.50. The firm has a market capitalization of $39.33 million, a price-to-earnings ratio of -2.99 and a beta of 0.56. Antibe Therapeutics has a one year low of $0.33 and a one year high of $0.89.

Antibe Therapeutics (OTCMKTS:ATBPFGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. As a group, sell-side analysts expect that Antibe Therapeutics will post -0.31 EPS for the current fiscal year.

Antibe Therapeutics Company Profile

(Get Free Report)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).

See Also

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.